Evidence Review
Key structural study (Mahmood et al., 2007). Published in Gut, this foundational study examined zinc carnosine's mechanisms in rat models and human gut cell lines. The compound stabilized tight junction proteins (occludin, claudin) at concentrations achievable in the gut lumen following oral dosing. It also demonstrated dose-dependent protection against gastric mucosal injury — a 38% reduction at 1 mg/ml and 75% reduction at 5 mg/ml. Separately, it promoted epithelial cell migration in wound-healing assays, suggesting active repair rather than passive protection [1].
Exercise gut permeability RCT (Davison et al., 2016). This four-arm, double-blind, placebo-controlled crossover trial enrolled 8 healthy volunteers who completed standardized exercise protocols at 2 and 14 days after beginning treatment. At baseline, the lactulose:rhamnose (L:R) ratio — a validated marker of gut permeability — was 0.32. After exercise, it rose 3-fold to 1.0 in the placebo arm. Fourteen days of zinc carnosine supplementation truncated this rise by approximately 70%, a finding that reached statistical significance. The combined zinc carnosine plus bovine colostrum arm showed no additional benefit over either alone [2].
Hewlings and Kalman review (2020). This narrative review in Nutrients compiled evidence across GI indications, including gastric ulcers (Japan approval), H. pylori eradication, NSAID-induced injury, oral mucositis, and radiation esophagitis. The authors concluded that the safety profile is well-established — no serious adverse events have been reported in clinical use spanning over two decades — and that the compound's localized mucosal adherence is the key mechanistic advantage over elemental zinc supplementation [3].
Efthymakis and Neri systematic review (2022). This more recent review examined human clinical data specifically, concluding that zinc carnosine has meaningful evidence for gastric ulcers, functional dyspepsia, and intestinal permeability conditions. The authors noted that while sample sizes in existing trials tend to be small, the consistency of findings across different GI pathologies is notable. They identified H. pylori eradication support and leaky gut as the most clinically relevant current applications and called for larger RCTs [4].
Li et al. on polaprezinc (2021). This review in Experimental and Therapeutic Medicine covered broader applications including radiation-induced mucositis, taste disorders in chemotherapy patients, and experimental models of sepsis and colitis. Mechanistically, the authors highlighted zinc carnosine's ability to scavenge reactive oxygen species, suppress NF-κB activation, and maintain mucosal prostaglandin levels — all contributing to its gastroprotective and anti-inflammatory profile [5].
Strength of evidence. The evidence base is moderate. Zinc carnosine has robust mechanistic data and a long clinical track record in Japan, where it has been used as a prescription drug for 30+ years. Human RCT data remains limited in scale — most trials have 10–50 participants — but the consistency of positive findings across leaky gut, H. pylori, NSAID injury, and inflammatory conditions is encouraging. This is not a compound where evidence is speculative; the mechanism is understood and the outcomes replicate across study types. The main open question is whether benefits persist long-term and whether the supplement form matches the pharmaceutical-grade compound used in Japanese trials.